Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• Regulated cell death (RCD) involves biomacromolecules and its dysregulation is linked to cancer development.
• Aberrant RCD pathways, including apoptosis, necroptosis, pyroptosis, PANoptosis, and ferroptosis, are implicated in hematological malignancies.
• Understanding RCD's role is crucial for developing effective cancer therapies.

Purpose of the Study:

• To review the aberrant mechanisms of various RCD subroutines in hematological malignancies.
• To explore the connections between RCD, tumorigenesis, immunotherapy, and drug resistance in blood cancers.
• To discuss novel therapeutic strategies targeting RCD in hematological malignancies.

Main Methods:

• Literature review and synthesis of existing research on RCD in hematological malignancies.
• Focus on specific RCD pathways: apoptosis, necroptosis, pyroptosis, PANoptosis, and ferroptosis.
• Analysis of the interplay between RCD, cancer development, immunotherapy, and drug resistance.

Main Results:

• Dysregulated RCD protein expression and localization contribute to cancer initiation and progression.
• Targeting specific RCD pathways with small-molecule compounds shows therapeutic potential.
• RCD modulation impacts anti-tumor immunity and overcomes drug resistance in hematological cancers.

Conclusions:

• Targeting RCD pathways represents a promising therapeutic strategy for hematological malignancies.
• Further research into RCD mechanisms can lead to improved anti-cancer treatments.
• Modulating RCD offers a multifaceted approach to combatting blood cancers and enhancing treatment efficacy.